This CPD activity is sponsored by Reckitt. All content is the true, accurate and independent opinion of the speakers and the views expressed are entirely their own.[/caption]
Sources: Australasian College of Pharmacy. Management of reflux: a guideline for pharmacists. Queensland Health. Queensland Community Pharmacy Gastro-oesophageal Reflux and Gastro-oesophageal Reflux Disease – Clinical Practice Guideline. NSW Health. NSW Pharmacist Practice Standards for gastro-oesophageal reflux and gastro-oesophageal reflux disease.[/caption]
Dr Ming S Soh PhD, BPharm (Hons)[/caption]
DR Amy Page (she/her) PhD, MClinPharm, GradDipBiostat, GCertHProfEd, GAICD, GStat, FSHPA, FPS is a consultant pharmacist, biostatistician, and the director of the Centre for Optimisation of Medicines at UWA’s School of Allied Health.[/caption]
Hui Wen Quek (she/her) BPharm(Hons), GradCertAppPharmPrac is a pharmacist and PhD candidate at the University of Western Australia (UWA).[/caption]
Gauri Godbole FPS[/caption]
Date of birth now required on all NSW scripts
From 1 November 2022, the date of birth of every patient must be included on all prescriptions for Schedule 4 and Schedule 8 medicines.
The scope of practice changes revolutionising health care access
It has been a big week for pharmacy scope of practice, with three states announcing changes to pharmacist prescribing.
Prescription rule changes to support telehealth
Australia’s Chief Health Officer has approved an amendment to PBS prescription requirements for telehealth consultations as an emergency measure during the COVID-19 response.
Navigating nausea and vomiting during pregnancy
Nausea and vomiting in pregnancy (NVP) is a prevalent pregnancy-induced condition, affecting an estimated 70% of all pregnancies.
How to save a life with naloxone
By providing non-judgemental and appropriate counselling on the use of naloxone, pharmacists can empower those who carry it to confidently intervene in the case of opioid toxicity.
FAQ: clozapine’s close checks
Clozapine, used for the management of treatment-resistant schizophrenia, is subject to strict regulatory and monitoring requirements.
